Ravindra Majeti -Assistant Professor, Division of Hematology, Stanford Cancer Center, Stanford Institute for Stem Cell Biology and Regenerative Medicine.
CD47 is a new potential target for elimination of leukemia-initiating cells in hematological malignancies.
We demonstrate not only that CD47 is more highly expressed on AML LSC compared to normal HSC and MPP but also that this differential expression can be used to separate normal HSC/MPP from leukemia cells.
Majeti R, et al. Cell 2009;138:286
Even CD47 “covers” conventional (CD34+/CD38-) leukemia stem cells in AML, it equally expressed in other leukemic cells.
This talk was recorded at the 2010 AACR annual meeting April 17.
If you’re looking for postdoc position, you should consider his lab. Apply now!
Related posts:
- Lecture: Irving Weissman – Cancer Stem Cells: The origin of cancer
- Lecture: Irving Weissman – Stem Cells: Units in Regeneration, Cancer, and Natural Selection
- Lecture: Michael Longaker – Regenerative Medicine: What Is It?
- How to separate cancer cells from normal stem cells?
- Hierarchy of human hematopoiesis – scheme is updated
{ 2 comments… read them below or add one }
Thanks Alex for posting
In your opinion, when CD47 MAB could be expected in human trials?
Yes, I think they will go for clinical trials with CD47.
As you hear from the lecture, his group recently did a lot of preclinical work to test the combination anti-CD47 + rituximab (anti-CD20) in Non-Hodgkin Lymphoma (NHL).
He told me that they in process for preparation of IND for FDA approval to start phase I of trial.